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RESUMO – Atualmente, na prática clínica, quando se observa uma criança com uma erupção pustulosa e inflamação sistémi-
ca, é mandatório pensar numa doença auto-inflamatória, após excluir uma causa infecciosa. Apesar de rara, a doença auto-
-inflamatória deve ser reconhecida o mais precocemente possível, diagnosticada corretamente (incluindo estudo genético), e 
tratada com terapia dirigida, se disponível.   
PALAVRAS-CHAVE – Criança; Dermatopatias Vesiculobolhosas/etiologia; Doenças da Pele/etiologia; Doenças Hereditárias 
Autoinflamatórias/complicações. 
Pustular Eruptions in Children as Manifestations of 
Autoinflammatory Diseases   
ABSTRACT – Nowadays, in clinical practice, when attending a child with a pustular eruption and systemic inflammation, it is 
mandatory to think of an autoinflammatory disease, once infectious causes have been ruled out. Although rare, autoinflammatory 
disease must be recognized as early as possible, accurately diagnosed (including gene testing), and treated with targeted therapy 
if available. 
KEYWORDS – Child; Hereditary Autoinflammatory Diseases/complications; Skin Diseases/etiology; Skin Diseases, Vesiculo-
bullous/etiology.
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INTRODUCTION
The monogenic autoinflammatory diseases (AIDs) are a 
group of disorders of dysregulation of innate immune sys-
tem, characterized by recurrent or continuous inflammation 
(usually manifested by elevated acute phase reactants), in 
the absence of the typical features of autoimmunity, such as 
autoantibodies or antigen-specific T lymphocytes.1 Since the 
first characterization of the genes underlying familial Medi-
terranean fever (FMF) in 1997, over 30 diseases have been 
included to the list of AIDs due to improvement in genetic 
sequencing and immunologic research.2-4
AIDs share an early onset, recurrent fevers, and a varia-
ble multisystemic involvement.2-8 The dermatologist assumes 
here a privileged role in the early diagnosis of an AID, since 
the skin is one of the major organs involved with urticaria, 
erysipela-like erythema, erythema nodosum-like lesions, 
pustular eruptions, acne and pyoderma gangrenosum.5-8
The purpose of this article is to review the monogenic 
AIDs that can present a pustular eruption in infants and chil-
dren, emphasizing their clinical manifestations. The classi-
fication of AIDs we use is based on clinical grounds, as it 
seems to be more useful for the clinician.5-10 (Table 1)
1. Deficiency of interleukin-1 receptor antagonist 
(DIRA) 
Deficiency of interleukin-1 receptor antagonist (DIRA) 
is an autosomal recessive AID, first described in 200911 
and with 19 patients reported to date,12 caused by loss-of 
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Tabela 1 - Summary of the characteristics of monogenic autoinflammatory diseases that present with pustular 
eruptions. 
SKIN MANIFESTATIONS OTHER MANIFESTATIONS
With inflammatory 
bone disease
Deficiency of IL-1 
receptor antagonist 
(DIRA)
Early onset pustulosis
Osteomyelitis
Periostitis
Elevated APR 
Majeed syndrome
Pustules
Sweet syndrome Psoriasis
Osteomyelitis
Anemia
Fever
With pyogenic 
arthritis
Pyogenic arthritis, 
pyoderma gan-
grenosum and acne 
syndrome
(PAPA)
Severe acne nodulo-cystic 
Pyoderma gangrenosum
Sterile pyogenic arthritis
With inflammatory 
bowel disease
Early-onset IBD Folliculitis
Enterocolitis
Perianal disease
Without other organ 
involvement
CARD14-mediated 
pustular psoriasis 
(CAMPS)
Generalized pustular psoriasis
Deficiency of IL-36 
receptor antagonist 
(DITRA)
Generalized pustular psoriasis
Fever
Elevated APR
Pyrin-associated 
autoinflammation 
with neutrophilic 
dermatosis (PAAND)
Severe acne 
Sterile skin abscesses 
Pyoderma gangrenosum 
Hidradenitis suppurativa 
Vasculitis
Fever 
Elevated APR
With 
immunodeficiency
PLCγ2-associated 
antibody deficiency 
and immune dys-
regulation (PLAID)
Cold induced urticaria 
Acral lesions
Granulomas 
Sinopulmonary infections
Hypogammaglobulinemia
Vitiligo and autoimmune 
thyroiditis
ANA positive
Autoinflamma-
tion and PLCγ2-
associated antibody 
deficiency and im-
mune dysregulation 
(APLAID)
Vesiculopustular lesions 
Recurrent erythematous plaques
Mild immunodeficiency
APR: acute phase reactants; PLCγ2: Phospholipase Cγ2.
147
Artigo de Revisão
Revista SPDV 77(2) 2019; Erupções pustulosas em crianças; Felicidade Santiago, Antonio Torrelo.
function mutations in the IL-1 receptor antagonist gene 
(IL1RN). The absence of the IL-1-receptor antagonist results 
in an uninhibited production of the proinflammatory cytoki-
ne IL-1.  The two major organs affected in this potentially 
life-threatening condition are the skin and bone.5-7,11
Patients with DIRA present, in the first months of life, 
with a pustular skin eruption (localized or generalized) over 
erythematous plaques, simulating a severe pustular psoria-
sis. Then skin can evolve to a diffuse ichthyosiform desqua-
mation. Pathergy and nail changes, such as onychomadesis, 
pitting and anonychia, are also observed. Stomatitis or oral 
ulcerations are present in some patients. Histological findin-
gs of the affected skin show extensive neutrophilic infiltration 
of the epidermis and dermis, subcorneal pustules, acantho-
sis and hyperkeratosis.2,4-8,10-15
Additionally, patients in the first months of life develop 
aseptic multifocal osteomyelitis and periostitis. Skeletal al-
terations on radiography include widening of the anterior 
rib ends and clavicles, periosteal elevation along multiple 
long bones, multifocal osteolytic lesions, heterotopic ossi-
fications, and cervical vertebral fusion secondary to collap-
sing vertebral osteolytic lesions.2,4-8,11-15 
Fever is often low-grade or can be absent in DIRA, 
however a persistent elevation of inflammatory markers 
(leukocytosis with neutrophilia, erythrosedimentation rate, 
C-reactive protein) is observed. Less frequent manifestations 
include interstitial lung disease, respiratory distress, he-
mophagocytosis, hepatosplenomegaly, hypotonia, venous 
thrombosis and central nervous system vasculitis. Preterm 
labour was described in almost all patients.4,6-8,11-15
The conjugation of these severe cutaneous and skeletal 
alterations, associated with a persistent elevation of the in-
flammatory markers, with negative cultures, should alert for 
DIRA. The detection of mutations in IL1RN is mandatory for 
a definitive diagnosis.6,9,13 
If not timely recognized or treated, DIRA can escalate 
to life-threatening systemic inflammation and death, with a 
mortality rate over 30% in early infancy.6,11-15 Concerning to 
treatment, daily injection of the recombinant IL-1 receptor 
antagonist (anakinra) is described to be lifesaving in these 
patients, leading to a rapid resolution of skin lesions and 
systemic inflammation. Long-term therapy with canakinu-
mab can replace anakinra with much fewer injections nee-
ded.4,6,7,10-15
2. Majeed syndrome
Majeed syndrome is an exceedingly rare autosomal re-
cessive AID, mostly identified in Middle Eastern families, 
caused by loss-of-function mutations in lipin 2 gene, which 
encodes LPIN2, a phosphatidate phosphatase important in 
lipid metabolism.4,9,16
Cutaneous alterations in Majeed syndrome are not al-
ways present, although patients can have a neonatal-onset 
recurrent pustular dermatitis, Sweet syndrome-like lesions 
and psoriasis.4-9,16-19  
Typical manifestations are chronic recurrent multifocal 
osteomyelitis (affecting clavicles, sternum and long bones) 
that starts early (3 weeks to 2 years of life) and congenital dy-
serythropoietic anemia. Other features include fever, hepa-
tomegaly, a retarded growth and joint contractures.2,5,7,9,16-19
This syndrome shares with DIRA the relevant osseous in-
volvement and the excellent therapeutic response to anakin-
ra.5,7,16-19
3. Pyogenic arthritis, pyoderma gangrenosum, 
and acne (PAPA) syndrome
The PAPA syndrome is an autosomal dominant AID 
described in 1997, caused at least in a few cases by gain-
-of-function mutations in the gene encoding CD2-binding 
protein 1, also known as proline-serine-threonine-phospha-
tase-interacting protein 1 (PSTPIP1). This results in abnormal 
inflammasome and innate immune cell activation and over-
-production of IL-1ß.2,5-9,20
Cutaneous manifestations include severe scarring nodu-
locystic acne that can begin in childhood or puberty and 
tends to persist into adulthood. The inflammatory charac-
ter of acne predominates, but retentional elements can 
also be present. Pathergy is frequent and may be induced 
early in life upon vaccination or minimal trauma. The other 
key features of this syndrome are pyoderma gangrenosum 
and childhood-onset flares of painful sterile monoarthritis, 
which can be deformating. By puberty, the joint symptoms 
tend to decrease and skin symptoms become more promi-
nent.5-9,20,21 
Fever is rarely observed in PAPA patients. Laboratory 
findings are non-specific and may include leukocytosis and 
increased erythrosedimentation rate and C-reactive protein 
during flares.6,20
Treatment of PAPA syndrome is challenging and depends 
on the dominant clinical manifestation. It can include corti-
costeroids, thalidomide, cyclosporine, dapsone, tacrolimus 
and intravenous immunoglobulin (IVIG) used with variable 
individual responses. Anakinra was also used with variable 
results, but monoclonal anti-TNF antibodies (infliximab, eta-
nercept and adalimumab) were considered more effective to 
treat skin alterations.4,6,7,9,10,20-24
Several other syndromes that conjugate acne and pyo-
derma have been reported in the literature, like PASH 
(pyoderma, acne and hidradenitis suppurativa), PAPASH 
(pyoderma, acne, pyogenic arthritis, and hidradenitis su-
ppurativa), PASS (pyoderma, acne, and seronegative spon-
dyloarthritis), PsAPASH (psoriatic arthritis, pyoderma, acne, 
and hidradenitis suppurativa), and PAC (pyoderma, acne, 
and ulcerative colitis). So far, PSTPIP1 mutations have been 
implicated in PASH, PAPASH and PAC syndrome.25-27
4. Early-onset inflammatory bowel disease (IBD)
Early-onset inflammatory bowel disease (IBD) is caused 
by loss-of-function mutations in interleukin-10 and interleu-
kin-10 receptors. These patients have refractory enterocolitis 
and perianal disease manifesting in the first year of life. The 
most frequent extraintestinal symptom is folliculitis followed 
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by oral aphthous lesions, arthritis, and hearing impairment. 
Other manifestations include fever, arthritis, and recurrent 
infections.4,28,29
This is a very severe disease, and hematopoietic stem cell 
transplantation was successful in the majority patients.4,28,29
5. Deficiency of IL-36 receptor antagonist (DITRA)
Deficiency of IL-36 receptor antagonist (DITRA) is a rare 
disease caused by homozygous or compound heterozygous 
mutations in the gene encoding the IL-36 receptor antago-
nist (IL-36RN), causing its deficiency and an exaggerated 
proinflammatory response in the nuclear factor-ƙB pathway, 
thus differing from IL-1receptor antagonist deficiency in pa-
tients with DIRA.5,6,7,30-32
DITRA was first described in 2011 when Marrakchi et al 
identified recessively inherited mutations in nine Tunisian fa-
milies with generalized pustular psoriasis (GPP). It was also 
later reported in sporadic GPP (both children and adults) 
without psoriasis vulgaris (PV). IL36RN mutations were also 
described in patients with acrodermatitis continua of Hallo-
peau, severe acute generalized exanthematous pustulosis 
and impetigo herpetiformis, as a genetic predisposing or 
causative factor.6,30-32
DITRA is clinically suspected when, early in childhood, a 
recurrent and sudden-onset diffuse, erythematous skin erup-
tion, with pustules, similar to a severe GPP appears (Fig. 1). 
Subsequent diffuse desquamation can be observed. Along 
with cutaneous findings, systemic symptoms are observed 
such as high-grade fever, asthenia, and elevation of in-
flammatory markers. Other clinical features are geographic 
tongue, nail dystrophy, arthritis and cholangitis.2,4,5,7,30,34 
Histopathological studies have shown intraepidermal spon-
giform pustules, acanthosis and parakeratosis in the stratum 
corneum, and infiltration of the skin by CD8 and CD3 T cells 
and macrophages.30
Although the disease usually occurs in childhood (be-
tween 1 week and 11 years of age in Marrakchi families), 
its occurrence in adults has also been described.  The fre-
quency of flares was variable and they were associated with 
viral or bacterial infections, withdrawal of retinoid thera-
py, menstruation, and pregnancy. The disease may be life 
threatening and death due to septicemia has been reported 
in 5 cases.30
Comparing to DIRA, DITRA patients can have higher 
fever and asthenia, but systemic involvement is less aggres-
sive.5
The majority of cases of GPP without PV are caused by 
recessive IL36RN mutations, so Hussain et al recommended 
that patients with GPP with an early-onset, systemic inflam-
mation and absence of PV, should be screened for IL36RN 
mutations.35,36
Optimal treatment is not yet entirely clear and similar 
treatments in patients with identical mutations result in diffe-
rent outcomes. Beyond the conventional anti-psoriatic syste-
mic treatment, there are case reports of variable response to 
IL-1 blockade (anakinra), infliximab, etanercept, adalimu-
mab, ustekinumab, and more recently, secukinumab, iden-
tifying IL-17 as a potential therapeutic target that warrants 
further investigation.4,6,7,30-34,37-39
6. CARD14-mediated pustular psoriasis (CAMPS)
Caspase recruitment domain family member 14 
(CARD14) is considered a key regulator of skin immune ho-
meostasis, being an activator of the nuclear factor-ƙB within 
the epidermis.6,9,40-42  
In 2012, gain-of-function mutations in CARD14 were 
identified as the cause of familial PV and familial pityriasis 
rubra pilaris (PRP). Later, other inflammatory skin disorders 
associated with CARD14 mutations/variants were added like 
GPP with PV, palmoplantar pustular psoriasis and psoriatic 
arthritis.6,28,40-43  
The term CARD14-associated papulosquamous eruption 
(CAPE) was recently introduced to describe the patients with 
CARD14 mutations that present characteristics of both pso-
riasis and PRP.41
CAMPS can present as a childhood-onset severe pustu-
lar psoriasis. Fever and other systemic manifestations are 
generally not present but can occur during skin superinfec-
tions.4,6,40 A rare gain-of-function variant (p.Glu138Ala) was 
reported in a sporadic patient with severe early-onset GPP.40 
Recently, another gain-of-function variant (p.Asp176His) 
has been reported, being a predisposing factor for GPP with 
preceding or concurrent PV, underlying 20% of GPP cases 
with PV in Japan.44
In 2014, AP1S3 mutations were found in 15 European 
patients with various forms of pustular psoriasis, including 
GPP.45,46 However, the majority of patients with GPP do not 
Figure 1 - Patient with a diffuse, erythematous and pustular skin erup-
tion, compatible with DITRA. 
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carry mutations in any of the three genes - IL36RN, CARD14, 
or AP1S3 -, probably indicating a condition with a complex 
mode of inheritance with more genes/genetic factors to be 
unveiled.46
The treatment includes the same options for moderate-
-to-severe psoriasis, and there is one report of successful 
response to ustekinumab.10,41,47
7. Pyrin-associated autoinflammation with neu-
trophilic dermatosis (PAAND)
Pyrin-associated autoinflammation with neutrophilic der-
matosis (PAAND) is a newly described AID by Masters et al in 
2016, resulting from mutations in the MEFV gene encoding 
pyrin. It differs from FMF by its autosomal dominant inheri-
tance, fever lasting weeks as opposed to days in FMF, and 
absence of amyloidosis and serositis.5,48,49
From a clinical point of view, PAAND is characterized 
by recurrent, childhood-onset episodes of neutrophilic der-
matosis, with severe acne, sterile skin abscesses, pyoderma 
gangrenosum, hidradenitis suppurativa, and neutrophilic 
small-vessel vasculitis. These episodes coexist with elevated 
acute-phase proteins, fever, and arthralgia/myalgia.48,49
PAAND shares some features with sterile pyogenic disor-
ders such as PAPA, PASH, and PAPASH syndromes.48,49
One patient was successfully treated with anakinra, after 
previously showing an inadequate response to corticosteroi-
ds and methotrexate, and other was treated with adalimu-
mab.49,50
8. Phospholipase Cγ2-associated antibody defi-
ciency and immune dysregulation (PLAID) / autoin-
flammation and PLCγ2-associated antibody deficiency 
and immune dysregulation (APLAID)
PLAID and APLAID are two allelic conditions that present 
with autoinflammatory phenotypes associated to an immu-
nodeficiency, caused by autosomal dominant gain-of-func-
tion mutations in phospholipase Cγ2 (PLAID – gene deletion 
of an inhibitory region and APLAID – missense hypermor-
phic mutations), an enzyme that plays a key role in the re-
gulation of immune responses.2,51-53
Cutaneous manifestations can be quite variable. PLAID 
phenotypes have cold-induced urticaria within the first year 
of life, neonatal-onset ulcerative cutaneous lesions in cold-
-sensitive regions of the body (spontaneous ulceration of 
the nasal tip, finger and toes), granulomatous skin lesions 
and atopy. APLAID leads to an early-onset papulo-pustular 
eruption in infancy, that evolved to recurrent erythematous 
plaques and vesiculopustular lesions that may worsen with 
heat and sun exposure (Fig. 2). Cutaneous histiocytic gra-
nulomas with accumulation of neutrophils in the upper der-
mis have been identified in APLAID.2,5,51-53
In both conditions patients also presented fever, si-
nopulmonary infections and common variable immuno-
deficiency. Distinctive findings of PLAID are autoimmune 
manifestations such as autoimmune thyroiditis and vitiligo 
with positive anti-nuclear antibodies.2,5,51-53
Patients with a history of cold urticaria, granulomatous 
skin disease or a history of acral lesions in the early neona-
tal period should be tested for PLCG2 mutations.52
APLAID patients were partially responsive to anakinra 
and to high-dose corticosteroids.51-53
CONCLUSION
The diagnosis of an AID should combine phenotypic 
features and gene testing. The dermatologist has here the 
opportunity to be the first to suspect an AID, when patients 
present cutaneous lesions associated with fever and mul-
tisystemic inflammation, mainly in the first year of life. 
Early identification of these entities is critical, as it will 
guide the approach and the adequate treatment, in order 
to minimize organ damage resulting from uncontrolled sys-
temic inflammation. An example is DIRA where therapy with 
anakinra can be lifesaving.2,5,9
Since there are no diagnostic criteria (with the exception 
of FMF), the genetic testing is recommended, although not 
always feasible, and must be interpreted cautiously, requi-
ring a precise correlation between all the specialties invol-
ved.2,9
Note: The first author received the Cabral Ascensão 
2018 scholarship from the SPDV for the realization of an 
internship training, in October of 2018, in the Service of 
Dermatology of the Hospital Universitario Niño Jesus, Ma-
drid, Espanha.
Nota: A primeira autora recebeu a Bolsa Cabral Ascen-
são 2018 da SPDV para a realização de estágio formativo, 
em Outubro de 2018, no Serviço de Dermatologia do Hos-
pital Universitario Niño Jesus, Madrid, Espanha.
Figure 2 - Patient with a papulopustular eruption compatible with 
APLAID. 
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